Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603

BACKGROUND: Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamoto, Yasuyuki, Yuki, Satoshi, Sawada, Kentaro, Nakamura, Michio, Muto, Osamu, Sogabe, Susumu, Shindo, Yoshiaki, Ishiguro, Atsushi, Sato, Atsushi, Tsuji, Yasushi, Dazai, Masayoshi, Okuda, Hiroyuki, Meguro, Takashi, Harada, Kazuaki, Sekiguchi, Mari, Okada, Kazufumi, Ito, Yoichi M, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355819/
https://www.ncbi.nlm.nih.gov/pubmed/35579511
http://dx.doi.org/10.1093/oncolo/oyac086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355819/
https://www.ncbi.nlm.nih.gov/pubmed/35579511
http://dx.doi.org/10.1093/oncolo/oyac086

Ejemplares similares